<DOC>
	<DOCNO>NCT00709254</DOCNO>
	<brief_summary>This study design assess single-dose multiple-dose PK safety parameter utilizing dosage 3 mL ( 500 µg/mL ) AeroLEF deliver via nebulization AeroEclipse BAN device . The study conduct opioid naïve subject block naloxone opioid receptor antagonist .</brief_summary>
	<brief_title>Study Single Multiple Doses Inhaled AeroLEF ( Liposome-Encapsulated Fentanyl ) Healthy Subjects</brief_title>
	<detailed_description>Period I : Subjects receive i.v.dose fentanyl ( 200 µg ) ( Treatment A ) . Period II : Subjects randomly assign receive either single-dose ( Treatment B ) multi-dose ( Treatment C ) AeroLEF . In multi-dose Treatment C group , subject receive dose 3 mL AeroLEF every 12 hour total five dos 3 day 4 week washout period cross Period III . Period III : Subjects Period II participate crossover study receive either multi-dose ( Treatment C , 5 dos 12 hour interval ) single dose ( Treatment B ) . Subjects Treatment B Treatment C instruct continue inhalation AeroLEF approximately one ( 1 ) minute beyond point nebulizer sputter ensure aerosolized medication deliver .</detailed_description>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>Nonsmoking male female minimum age least 18 year Body weight aBMI range 18.5 27 , minimum weight least 60 kg . Availability subject entire study period willingness adhere protocol requirement , evidence sign , write , Informed Consent Form . Normal finding physical examination , vital sign ( blood pressure 100140 6090 mmHg , heart rate 5599 beats/min , respiration rate 1220 minute ) 12 lead ECG . Negative drug abuse , nicotine , alcohol , hepatitis Bsurface antigen , hepatitis C HIV . If female childbearing potential , patient must negative urine pregnancy test screen baseline . No clinical laboratory value outside Principal Investigator 's acceptable range , unless Principal Investigator decide subject 's value clinically significant . Female subject : ( ) premenopausal , regular menstrual cycle ( 2832 day ) , ( b ) pregnant prior study start avoids pregnancy study 1 month post drug administration , ( c ) surgically sterile least 6 month prior enrollment , ( ) postmenopausal least 1 year prior enrollment . Known history hypersensitivity fentanyl . Presence history cardiac , pulmonary , gastrointestinal , endocrine , neuromuscular , neurologic , hematological , liver kidney disease , condition know interfere absorption , distribution , metabolism , excretion drug . History drug abuse narcotic dependency . Use prescription medication within 30 day precede entry int study , include enzyme inducing/inhibitory drug ( exclude contraceptive ) . Participating clinical trial investigational drug within 30 day precede trial . Blood donation within 45 day precede trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>AeroLEF</keyword>
	<keyword>fentanyl</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>liposome</keyword>
	<keyword>encapsulate</keyword>
</DOC>